In a recent Toxicological Sciences study, scientists assess the challenges presented by cannabinoid vaping products during the analysis of their effect on consumers’ respiratory health.
Cannabinoid vaping products
Some of the common cannabinoid vaping products include D9-tetrahydrocannabinol (D9-THC), D8-tetrahydrocannabinol (D8-THC), as well as cannabidiol (CBD) products.
Several studies related to e-cigarettes or vaping have indicated the adverse effects, particularly in terms of their ability to cause lung injury, associated with cannabinoid vaping products. According to a February 2020 United States Centers for Disease Control and Prevention (CDC) report, 2,807 individuals were hospitalized and 68 deaths occurred due to utilizing cannabinoid vaping products.
Several studies have shown that among e-cigarette/cannabis vaping users with product use-associated lung injury (EVALI), 82% reported the use of THC vaping products, while only 16% reported using CBD vaping products.
A need for more research on the toxicity of cannabis vaping products
In the current study, scientists conducted toxicological profiles of cannabinoid vaping products. Herein, they assessed the relevant dose-response patterns, the toxicity of additives and diluents, and inhalational exposures to inform federal policy.
In vitro experiments examining the effect of CBD vaping product exposure on airway epithelial cells have revealed a high concentration of toxicity markers present in exposed cells. Some of these markers include cellular reactive oxygen species and those involved in cytotoxic processes and inflammation.
Source: News Medical